Ono Pharma USA Inc
28
0
1
24
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
10.7%
3 terminated/withdrawn out of 28 trials
88.9%
+2.4% vs industry average
0%
0 trials in Phase 3/4
13%
3 of 24 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (28)
A Study of Effectiveness and Safety of the First-Line Nivolumab Plus Ipilimumab With or Without Chemotherapy for Advanced/Recurrent Non-Small Cell Lung Cancer in Japan
Role: collaborator
Placebo-Controlled Study of ONO-2333Ms in Patients With Recurrent Major Depressive Disorder
Role: lead
Safety and Effectiveness of Nivolumab in Recurring Kidney Cancer Participants
Role: collaborator
BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC)
Role: collaborator
Effectiveness and Safety of Nivolumab in Participants That Have Head and Neck Cancer That Has Come Back or Has Spread
Role: collaborator
Phase I Biomarker Study (BMS-936558)
Role: collaborator
Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma
Role: collaborator
A Phase 2, Multi-center Study to Evaluate the Efficacy and Safety of ONO-2952 in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)
Role: lead
Study to Evaluate the Effects of ONO-2952 on Pain Perception Produced by Rectal Distention in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)
Role: lead
A Study of the Safety and Efficacy of ONO-7746 in Adult Cancer Patients With Chemotherapy Induced Thrombocytopenia
Role: lead
A Placebo and Active Controlled Study of ONO-6950 in Asthmatic Patients
Role: lead
A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
Role: lead
An Open-label, Single-dose, Intravenous Administration Study of ONO-2745/CNS 7056 in Subjects With Chronic Hepatic Impairment
Role: lead
Single and Multiple Dose Escalation and Two-sequence Crossover Study of ONO-9054 in Patients With Ocular Hypertension or Mild Open-angle Glaucoma
Role: lead
ONO-2952 Single-dose PET Study in Healthy Adult Subjects
Role: lead
A Placebo and Active Controlled Study of ONO-6950 Following Allergen Challenge in Patients With Asthma
Role: lead
Controlled Study of ONO-1101 in Patients With Postoperative Tachyarrhythmias in Japan
Role: lead
A Phase II Study to Evaluate the Effects of Oral ONO-5129 in Type 2 Diabetes Mellitus
Role: lead
A Study to Evaluate the Effects of ONO-2506 Intravenous Infusion in Patients With Acute Ischemic Stroke
Role: lead
Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ONO-2952 in Healthy Adult Subjects
Role: lead